within Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AX29_Fostemsavir;

model Fostemsavir
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C_enteral(
    weight = 70,
    F = 0.26,
    Cl = 4.9722222222222224e-06,
    adminDuration = 600,
    adminMass = 600 / 1000000,
    adminCount = 1,
    Vd = 0.189,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.0105,
    Tlag = 15.0,
    Vdp = 0.399,
    k12 = 5.611111111111111e-06,
    k21 = 5.611111111111111e-06);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Fostemsavir</td></tr><tr><td>ATC code:</td><td>J05AX29</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>600</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>189</td><td>L</td></tr>
    <tr><td>clearance:</td><td>17.9</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Fostemsavir is an antiretroviral medication used for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection for whom an otherwise suppressive antiretroviral regimen is not available. It is a prodrug of temsavir, which acts as an attachment inhibitor binding to gp120 on HIV-1, preventing virus attachment and entry into host CD4+ cells. Fostemsavir is FDA- and EMA-approved.</p><h4>Pharmacokinetics</h4><p>Population pharmacokinetics of temsavir (the active moiety of fostemsavir) in HIV-1-infected adults, following oral administration of fostemsavir 600 mg twice daily.</p><h4>References</h4><ol><li><p>Magee, M, et al., &amp; Moore, K (2021). Effect of Renal and Hepatic Impairment on the Pharmacokinetics of Temsavir, the Active Moiety of Fostemsavir. <i>Journal of clinical pharmacology</i> 61(7) 939–953. DOI:<a href=\"https://doi.org/10.1002/jcph.1810\">10.1002/jcph.1810</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33368327/\">https://pubmed.ncbi.nlm.nih.gov/33368327</a></p></li><li><p>Beran, C, et al., &amp; Sahloff, EG (2024). A Narrative Review of Novel Agents for Managing Heavily Treatment-Experienced People Living With HIV. <i>The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians</i> 40(4) 194–201. DOI:<a href=\"https://doi.org/10.1177/87551225241259894\">10.1177/87551225241259894</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/39157636/\">https://pubmed.ncbi.nlm.nih.gov/39157636</a></p></li><li><p>Landry, I, et al., &amp; Bertz, RJ (2016). Model-Based Phase 3 Dose Selection for HIV-1 Attachment Inhibitor Prodrug BMS-663068 in HIV-1-Infected Patients: Population Pharmacokinetics/Pharmacodynamics of the Active Moiety, BMS-626529. <i>Antimicrobial agents and chemotherapy</i> 60(5) 2782–2789. DOI:<a href=\"https://doi.org/10.1128/AAC.02503-15\">10.1128/AAC.02503-15</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/26902761/\">https://pubmed.ncbi.nlm.nih.gov/26902761</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.J.J05AX29 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Fostemsavir;
